The ppt cover General Introduction to the topic,
Description of CHI-SQUARE TEST, Contingency table, Degree of Freedom, Determination of Chi – square test, Assumption for validity of chi - square test, Characteristics , Applications, Limitations
The ppt cover General Introduction to the topic,
Description of CHI-SQUARE TEST, Contingency table, Degree of Freedom, Determination of Chi – square test, Assumption for validity of chi - square test, Characteristics , Applications, Limitations
This test (as a non-parametric test) is based on frequencies and not on the parameters like mean and standard deviation.
The test is used for testing the hypothesis and is not useful for estimation.
This test possesses the additive property as has already been explained.
Please Subscribe to this Channel for more solutions and lectures
http://www.youtube.com/onlineteaching
Chapter 9: Inferences from Two Samples
9.4: Two Variances or Standard Deviations
univariate and bivariate analysis in spss Subodh Khanal
this slide will help to perform various tests in spss targeting univariate and bivariate analysis along with the way of entering and analyzing multiple responses.
linearity concept of significance, standard deviation, chi square test, stude...KavyasriPuttamreddy
Linearity concept of significance, standard deviation, chi square test, students T- test, ANOVA test , pharmaceutical science, statistical analysis, statistical methods, optimization technique, modern pharmaceutics, pharmaceutics, mpharm 1 unit i sem, 1 year m
pharm, applications of chi square test, application of standard deviation , pharmacy, method to compare dissolution profile, statistical analysis of dissolution profile, important statical analysis, m. pharmacy, graphical representation of standard deviation, graph of chi square test, graph of T test , graph of ANOVA test ,formulation of t test, formulation of chi square test, formula of standard deviation.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
2. INTRODUCTION TO TERMS
1. PARAMETRIC TEST: The test in which the population constants like mean,
standard deviation, standard error ,correlation coefficient etc. and data tends to follow
one assumed or established distribution such as normal, Poisson etc.
2. NON PARAMETRIC: The test in which no constant of a population is used. Sdata do
not follow any specific distribution and no assumptions are made in these tests. Ex:
classifying good, better best.
3. HYPOTHESIS: it is a definite statement about the population parameters.
3. INTRODUCTION TO TERMS
4. NULL HYPOTHESIS: states there is no association between two cross tabulated variables in the population
and therefore the variables are statistically independent.
Ex: if we want to compare 2 methods A and B and if the assumption is that both the methods are
equally good is null hypothesis.
5. ALTERNATIVE /RESEARCH HYPOTHESIS: proposes that the two variables are related in the population. If
we assume that from 2 methods , method A is superior than method B , then this assumption is called Alternative
hypothesis.
6.CONTINGENCY TABLE: when the table is prepared by enumeration of qualitative data by entering the actual
frequencies , an if the table represents occurrence of two sets of events , the table is called contingency table. It
is also called association table.
4. INTRODUCTION TO TERMS
7. DEGREES OF FREEDOM: it denotes to the extent of independence (freedom) enjoyed by a
given set od observed frequencies . Suppose we are given a set of n observed frequencies which
are subjected to k independent constraints ( restrictions) then,
df=(number of frequencies)-(number of independent constraints on them)
In other terms df=(r-1)(C-1)
WHERE r= no of rows
c=no of columns
5. INTRODUCTION TO CHISQUARE
•The chi-square test is an important test amongst the several tests of significance developed by
statisticians.
•It was developed by Karl Pearson in 1990.
•It is a non parametric test not based on any assumption or distribution of any variable.
•This statistical test follows a specific distribution known as chi-square distribution.
•In general the test we use to measure the differences between what is observed and what is
expected according to an assumed hypothesis is called chi-square test.
6. CHARACTERISTICS
•The test is based on frequencies and not on the parameters like mean and SD.
•The test is used for testing the hypothesis and is not useful for estimation
•Applied to a complex contingency table with several classes and such a very useful test in
research work.
•This test is an important non parametric test as no rigid assumptions are necessary in regard to
the type of population , no need of parameter values and relatively less mathematical details are
involved.
7. Chi square distribution
•If 𝑥1 , 𝑥2 …. Are independent normal variates and each is
distributed normally with a mean zero and SD as unity , then
X12+X22+…….Xn2 = ∑Xi2 is distributed as chi-square with n
degrees of freedom when n is large. The chi-square curve for df
N=1,5 and 9 is as follows
• if DF >2: distribution is bell shaped
•if DF =2: distribution is L shaped with maximum ordinate 0
•if DF >2: distribution is L shaped with infinite ordinate at the origin
9. TEST OF GOODNESS OF FIT
•This test enables us to see how well does the assumed theoretical distribution ( such as
binomial or normal distribution) fit to the observed data.
•Formula 𝑥2
=
𝑜−𝑒 2
𝑒
•Where o= observed frequency and e=expected frequency
•If 𝑥2caluculated is > than table value then null hypothesis is rejected
10. TEST OF independence of attributes
•Test enables us to explain whether or not two attributes are associated.
•For instance, we may be interested in knowing whether a new medicine is effective in controlling fever or not, 𝑥2
test
is useful.
•In such situation we proceed with the null hypothesis that the 2 attributes ( new medicine and control of fever) are
independent which means the new medicine is not effective in controlling fever.
•The calculated value is greater than table value at a certain level of significance for a given df the H0 is rejected and
viceversa.
•When H0 is rejected it can be concluded that there is a significant association between 2 attributes.
11. TEST OF HOMOGENITY
•This test can also be used to test whether the occurance of events follow uniformity or not
• Ex: admission of patients in govt hospital in all days of week is uniform or not
• Chisquare less than tabulated value then null hypothesis is accepted , and it can be concluded that there is a uniformity in the
occurance of the events ( uniformity of patients getting admitted throughout the week)
12. calculation
• 𝑥2 =
𝑜−𝑒 2
𝑒
• Where o= observed frequency and e=expected frequency
• If 𝑥2
calculated is > than table value then null hypothesis is rejected
•If two distributions are exactly alike chisquare is zero which is mostly due to sampling error.
• generally it is not equal to zero
13. Steps in calculation
1. Calculate the expected frequencies and the observed frequencies
2. Expected frequencies: the cell frequencies that would be expected in a contingency table if the two variables
were statistically independent.
3. OBSERVED FREQUENCIES: the cell frequencies actually observed in a contingency table.
𝑓𝑒= (column total)(row total)
N
To obtain the expected value for nay cell in any cross tabulation in which the 2 variables are assumed independent ,
multiply the row and column totals for that cell and divide the product by the total number of cases in the table.
14. CONDITIONS FOR APPLICATION
1. The data must be in the form of frequencies
2. The frequency data must have a precise numerical value and must be organized into categories or groups
3. Observations recorded and used are collected on a random basis.
4. All the items in the samples must be independent.
5. No group should contain very few items, say less than 10. in case where the frequencies are less than 10,
regrouping is done by combining the frequencies of adjoining groups so that the new frequencies become
greater than 10.
6. The overall number of items must be reasonably high . It should be generally be at least 50.
15. Yates correction
If the 2x2 contingency table , the expected frequencies are small say less than 5 , the chi-square test cant be used .
In that case the direct formula of the test cant be used . So we can use yates correction formula.
16. LIMITATIONS
◦ The data is from a random sample
◦ This test is applied in four fold table , will not give a reliable result with one degree of freedom if the expected value
in any cell is less than 5. in such case yates correction is necessary.
◦ Even if yates correction, the test may be misleading if any expected frequency is much below than 5. in that case
another appropriate test should be applied
◦ In contingency tables larger than 2X2. yates correction cannot be applied.
◦ Interpret this test with caution if sample total or total of values in all cells is less than 50.
17. Problem-1
◦ In an antimalarial camp ,in a certain area chloroquine was administered to 812 people out of the population of
3248. The number of fever cases shown are:
TREATMENT FEVER NO FEVER
CHLOROQUIN 20 792
NO CHLOROQUIN 220 2216
18. Problem-1
◦ 1. Formulate the null and alternate hypothesis
◦ H0: chloroquine is not effective against malaria
◦ H1: chloroquine is effective against malaria
◦ 2. Make contingency table
Treatment Fever No fever Total
Chloroquin 20 792 812
No chloroquin 220 2216 2436
Total 240 3008 3248
19. Problem-1
◦ Find out the expected frequencies
◦ E=RTXCT/ Grand total
E1=240X812/3248 =60
E2=240X2436/3248 = 180
E3=3008X812/3248 = 752
E4 = 3008 X 2436 / 3248 =2256
20. Problem-1
o e O-e (O-e)2 (O-e)2/e
20 60 -40 1600 1600/60=26.6
220 180 +40 1600 1600/180=8.8
792 752 +40 1600 1600/752=2.12
2216 2256 -40 1600 1600/2256=0.7
38.39
Df=(2-1)(2-1)=1
At 5% level of significance with1 as df the table value of 𝑋2 is 3.84 which is less than the calculated value .
Hence the hypothesis H0 is rejected and H1 is accepted.
21. Problem-II
◦ The table shown is given the data during the epidemic of cholera. Check the effect of inoculation on cholera.
TREATMENT ATTACKED NOT ATTACKED
Inoculated 31 469
Not Inoculated 185 1315
22. Problem-II
◦ 1. Formulate the null and alternate hypothesis
◦ H0: there will be no effect of inoculation in preventing the attack of cholera
◦ H1: there will be some effect of inoculation on cholera
2. Make contingency table
TREATMENT ATTACKED NOT ATTACKED TOTAL
Inoculated 31 469 500
Not Inoculated 185 1315 1500
Total 216 1784 2000
23. Problem-II
◦ Find out the expected frequencies
◦ E=RTXCT/ Grand total
E1=500X216/2000 =54
E2=216X1500 / 2000 = 162
E3=500X1784 / 2000= 446
E4 = 1500 X 1784 / 2000 =1338
TREATMENT ATTACKED NOT
ATTACKED
TOTAL
Inoculated 31 469 500
Not Inoculated 185 1315 1500
Total 216 1784 2000
24. Problem-II
o e O-e (O-e)2 (O-e)2/e
31 54 -23 529 9.79
185 162 23 529 3.26
469 446 23 529 1.18
1315 1338 23 529 0.39
14.62
Df=(2-1)(2-1)=1
At 5% level of significance with1 as df the table value of 𝑋2 is 3.84 which is less than the calculated value .
Hence the hypothesis H0 is rejected and H1 is accepted.